Browse by author
Lookup NU author(s): Dr Emma ScottORCiD, Professor David Elliott, Dr Jennifer Munkley
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020 Elsevier B.V. While the development of immunotherapies for cancer treatment offer significant promise across several cancers, still only a small subset of patients respond to immune based monotherapies. As such, attention has turned to the development of combination therapies. These use conventional cancer treatments such as chemotherapy to sensitise tumours to immunotherapy. Here, we summarise key research, highlighting the exciting potential of tumour associated glycans as therapeutic targets to sensitise tumours to immunotherapy. When cells undergo carcinogenesis they reprogram their glyco-code. Several cancer associated glycans have been identified, and therapies targeting them are under development. Proteins containing carbohydrate binding domains (lectins) are expressed by many immune cell subtypes, and upon glycan binding, transduce immune modulatory signals that regulate the tumour immune microenvironment.
Author(s): Scott E, Elliott DJ, Munkley J
Publication type: Review
Publication status: Published
Journal: Clinica Chimica Acta
Year: 2020
Volume: 502
Pages: 167-173
Print publication date: 01/03/2020
Online publication date: 20/12/2019
Acceptance date: 17/12/2019
ISSN (print): 0009-8981
ISSN (electronic): 1873-3492
Publisher: Elsevier B.V.
URL: https://doi.org/10.1016/j.cca.2019.12.015
DOI: 10.1016/j.cca.2019.12.015
PubMed id: 31870793
